Citations with the tag: DRUGS -- Prices

Results 1 - 50

• Price of prescription drugs: Depends on how you look at it.
   // Medical Marketing & Media; Aug97, Vol. 32 Issue 8, p25 

  Focuses on the price increase trend of prescription products in the first quarter of 1997 in the United States. Factors that affected the increase of pharmacy costs; Impact of the price increase on the practice of medicine.

• Rx prices rise 2.3 percent.
   // Medical Marketing & Media; Oct97, Vol. 32 Issue 10, p24 

  Reports on the rise of overall prices of prescription drugs in the second quarter of 1997 in the United States. Increase in prices of branded products; Decrease on the overall prices for generics.

• Rx drug prices rise 2.9 percent.
   // Medical Marketing & Media; Jan1998, Vol. 33 Issue 1, p22 

  Reports on the rise in prices of prescription pharmaceuticals in the third quarter of 1997 as compared to the same period a year ago in the United States. Drop of overall prices of generic drugs; Rise in the prices of branded prescription drugs.

• Regulating the price of patented drugs.
  Buske, Lynda // CMAJ: Canadian Medical Association Journal; 05/15/97, Vol. 156 Issue 10, p1512 

  Focuses on drug prices in Canada from the 1988 to the 1990s. Drop in drug expenditures increases between 1987 and 1994; Price increases for patented and nonpatented drugs.

• Drug makers modify pharmacy-suit settlement.
  Buske, Lynda // AHA News; 5/13/96, Vol. 32 Issue 19, p5 

  Reports that the 13 drug companies sued by retail pharmacies have agreed to charge the retailers the same price as managed care groups.

• Coalition seeks access to drug discounts.
  Buske, Lynda // AHA News; 1/27/97, Vol. 33 Issue 3, p3 

  Reports that cooperative purchasing of drugs does not increase overall prices according to a study made by Public Hospital Pharmacy Coalition.

• International page.
  Buske, Lynda // DCI; Apr94, Vol. 154 Issue 4, p9 

  Reports on the setback of Europe's move to phase out price controls on pharmaceuticals when the European Union's Executive Commission rejected the notion.

• The comparison shopper.
  Buske, Lynda // Drug Store News; 2/20/95, Vol. 17 Issue 3, p23 

  Compares prices of various drugs offered by warehouse clubs and drug stores in the United States as of February 1, 1995. Includes Opti-free; Extra-Strength Excedrin; Tylenol gelcaps.

• The art (and science) of pricing prescriptions.
  Buske, Lynda // Drug Store News; 2/12/96, Vol. 18 Issue 3, p25 

  Focuses on the pricing of prescription drugs in the United States, based on statistical data provided by ProfitLink McKesson Corp. Variation of prescription drug pricing from region to region; Pricing of the top 15 drugs in the midwestern and southern states; Division between the top 200 drugs...

• Drug price increases slow, but not enough for retail.
  Rankin, Ken // Drug Store News; 3/3/97, Vol. 19 Issue 5, p13 

  Focuses on the increasing cost of drugs to retail pharmacies and their customers in the United States. Overall drug prices as measured by the government's Producer Price Index in 1996; Measurement of changes in the cost of prescription drugs; Insights offered by the different tools for tracking...

• Changes in producer and consumer price indices.
  Rankin, Ken // Drug Topics; 7/19/93, Vol. 137 Issue 14, p57 

  Presents graphs of consumer and producer prices of prescription and over-the-counter drugs within a five month period starting from January to May, 1993.

• Lower price increases for drugs.
  Rankin, Ken // Drug Topics; 8/16/93, Vol. 137 Issue 16, p6 

  Reports on a study by First DataBank on increase in drug prices. Comparison of drug price increases in 1993 and 1991.

• Walsh America/PMSI--latest reports.
  Rankin, Ken // Drug Topics; 8/16/93, Vol. 137 Issue 16, p55 

  Presents the increase in consumer Rx drug prices in the first six months of 1993. Overall inflation rate; Year to date brand share; Average retail past; Rx size in units; Average cost/day to customer; Number of days' therapy.

• Rx prices outpace other sectors and both PPI and CPI.
  Rankin, Ken // Drug Topics; 11/22/93, Vol. 137 Issue 22, p6 

  Details the 4.2 percent rise of pharmaceutical prices from October 1992 to 1993 as measured by the Labor Department's producer price index (PPI). Climb of overall PPI during the same period; Retail pharmaceutical price increase as measured by the consumer price index (CPI); CPI increase from...

• $3-a-day capsules!
  Plagakis, Jim // Drug Topics; 11/22/93, Vol. 137 Issue 22, p20 

  Illustrates the reaction of consumers to expensive medications being sold at pharmacies all over United States. Hillary Brigade; Expense of regaining a lost quality of life; Complaints about brand-name pharmaceutical manufacturers; Author's opinion about informing Americans about the cost of...

• Medicare Rx prices: Higher here or there?
  Conlan, Michael F. // Drug Topics; 8/22/94, Vol. 138 Issue 16, p65 

  No abstract available.

• Studies renew price-curb talk.
  Weissenstein, Eric // Modern Healthcare; 2/7/94, Vol. 24 Issue 6, p17 

  Reports on two Congressional studies on the pharmaceutical industry's pricing policies. Calls for regulation by lawmakers; Rise in drug prices in 1993; Comparison with retail inflation rate; Cost differences between the United States and Great Britain.

• Pharma index.
  Lerner, Matthew // Chemical Market Reporter; 10/28/96, Vol. 250 Issue 18, p12 

  Compares current, last month, and year-ago prices of representative pharmaceutical materials for the week ending October 25, 1996.

• HCFA taking hard look at drug costs.
  Lerner, Matthew // Drug Topics; 11/7/94, Vol. 138 Issue 21, p8 

  Reports that the Health Care Financing Administration is trying to develop an estimate of the difference between the actual acquisition cost of prescriptions and the AWP.

• Rx price rise.
  Lerner, Matthew // Drug Topics; 1/23/95, Vol. 139 Issue 2, p52 

  Reports on the increase of prices pharmaceuticals in the United States in 1994.

• Retail Rx brand prices up 3.3%.
  Lerner, Matthew // Drug Topics; 3/4/96, Vol. 140 Issue 5, p8 

  Reports on the increase in retail prices for brand drugs in 1995, according to a report from IMS America. Decline of generic prices; Overall drug prices for all classes of trade for the year.

• R.Ph.s seek preliminary injunction.
  Lerner, Matthew // Drug Topics; 4/22/96, Vol. 140 Issue 8, p7 

  Reports that lawyers representing pharmacists in a Chicago, Illinois class action lawsuit are seeking a preliminary injunction that would require drugmakers to end pricing based on the status of the buyer and to offer discounts to buying groups that can demonstrate an ability to affect market...

• PDF may oppose class action settlement.
  Lerner, Matthew // Drug Topics; 6/10/96, Vol. 140 Issue 11, p9 

  Reports that the California-based Pharmacy Defense Fund may oppose the settlement of community pharmacy's price-fixing lawsuit with 11 brand-name companies. Concerns stated before a US District Court; Letter to contributors.

• Slowdown.
  Ukens, Carol // Drug Topics; 6/10/96, Vol. 140 Issue 11, p158 

  Reports on IMS America data on drug prices in the first quarter of 1996. Retail pharmacy prices; Brand drugs; Generic prices; Prescription drug prices.

• New service shows Rx price variations across U.S. regions.
  Muirhead, Greg // Drug Topics; 7/22/96, Vol. 140 Issue 14, p39 

  Focuses on the service called NetPayRX, which tracks the variations in the retail prices of prescription drugs in different regions in the United States. Process of the service; Comparison of the Lopid tablet in New York and California.

• Drug price hikes peaked in fourth quarter.
  Muirhead, Greg // Drug Topics; 3/2/98, Vol. 142 Issue 5, p8 

  Reports that there was an increase in drug prices in the fourth quarter of 1997, highlighting information from IMS America's Quarterly Pricing Report. Possible reason for this increase; Statistical information on this increase.

• Lower-priced pharmaceuticals promised.
  Joseph, Ray // Nutrition Health Review: The Consumer's Medical Journal; 1994, Issue 69, p17 

  Reports on drug manufacturers' promise of price reductions. Benefit of the price reduction to patients in constant need of medication for diseases such as allergies and arthritis; Anticipated increase in competition.

• Pharma index.
  Lerner, Matthew // Chemical Market Reporter; 09/29/97, Vol. 252 Issue 13, p14 

  Presents a chart reflecting price index for pharmaceuticals in the United States for the week ended September 26, 1997.

• The French way of controlling drug costs.
  Watson, Rory // BMJ: British Medical Journal (International Edition); 4/22/95, Vol. 310 Issue 6986, p1028 

  Describes an experiment introduced in France in 1994 to reduce the annual rise in public expenditure on drugs without affecting health care. Strategies used to persuade doctors to prescribe economically; Authorities' agreements with pharmaceutical companies involving them in the shared aim of...

• Prescription drug prices rise slightly.
  Watson, Rory // H&HN: Hospitals & Health Networks; 3/20/94, Vol. 68 Issue 6, p30 

  Reports on First DataBank's findings on the average price increase for all prescription drug products. Top 25 pharmaceutical companies with lower average increases; Higher rate of increase for generic products.

• The PPI for drugs: A five-year trend.
  Watson, Rory // H&HN: Hospitals & Health Networks; 2/20/95, Vol. 69 Issue 4, p16 

  Reports on the five-year trend for the producer price index for pharmaceuticals. Steady decline; Competitive cost-containment in the marketplace; Source of data.

• Extreme answers to prescription drug costs.
  Colhoun, Alexander // Christian Science Monitor; 4/18/2000, Vol. 92 Issue 102, p3 

  Reports that elderly citizens of the United States that live near the border with Canada often travel there to purchase pharmaceuticals at a much lower cost than that for which they available in the US, and discusses government concern over this fact.

• Drug prices race past inflation rate.
  Colhoun, Alexander // Nation's Health; Mar93, Vol. 23 Issue 3, p11 

  Reports that prescription drug prices continue to outpace the rate of inflation. Recent report by the Senate Special Committee on Aging which shows that drug manufacturers raised prices; Comment from committee chairman Sen. David Pryor; Proposal to curtail generous tax breaks and patent rights...

• EU attempts to tackle parallel pricing of drugs.
  Watson, Rory // BMJ: British Medical Journal (International Edition); 06/13/98, Vol. 316 Issue 7147, p1769 

  States that the European Union is conducting an investigation into the different prices charged on the same medications in member states. Factors which influenced investigations; Who is responsible for enforcing drug costs; What influences the costs of medicine.

• Modest price hikes for Rx drugs.
  Watson, Rory // DCI; Oct93, Vol. 153 Issue 4, p6 

  Reports on the average price increases of prescription drugs in the first half of 1993. Lowest average increase in the top 25 pharmaceutical companies; Governmental and market pressures to hold down prices; Deliberations on President Bill Clinton's health care legislation.

• Pharma index.
  Lerner, Matthew // Chemical Market Reporter; 05/26/97, Vol. 251 Issue 21, p12 

  Presents a chart depicting prices of representative pharmaceuticals in the United States, for the week ending May 23, 1997. Previous month and year figures.

• Why Drugs Cost So Much.
  Lerner, Matthew // Wilson Quarterly; Spring2003, Vol. 27 Issue 2, p101 

  Presents a review of the article 'America's Other Drug Problem,' by Arnold S. Relman and Marcia Angell, which appeared in the December 16, 2002 issue of 'The New Republic.'

• Crossing Boundaries.
  White, Cissy // Revolution: The Journal for RNs & Patient Advocacy; Nov/Dec2002, Vol. 3 Issue 6, p9 

  Reports on the Act to Establish Fairer Prescription Drug Prices in Maine. Negotiation of cheaper prices of drugs; Discounts availed by senior citizens.

• Judge OKs drug-pricing settlement.
  White, Cissy // AHA News; 07/01/96, Vol. 32 Issue 26, p5 

  Reports on the $351.3 million settlement emanating from claims against pharmaceutical companies' denial of discounts given to hospitals and health maintenance organizations to their retail counterparts.

• Pharma index.
  Lerner, Matthew // Chemical Market Reporter; 11/24/97, Vol. 252 Issue 21, p12 

  Presents the price index for pharmaceutical products in the United States for the week ending November 21, 1997.

• Pharma index.
  Lerner, Matthew // Chemical Market Reporter; 12/29/97, Vol. 252 Issue 26, p10 

  Presents a chart reflecting prices of eight representative materials in the pharmaceutical industry for the week ending December 26, 1997.

• THE PLOTS TO KEEP DRUG PRICES HIGH.
  Tully, Shawn; Davis, Joyce E. // Fortune; 12/27/1993, Vol. 128 Issue 16, p120 

  Reveals the plots by the federal government and America's retail pharmacies to keep drug prices high by threatening to halt the wave of competition in drug pricing that is just beginning to catch on. Competition for expensive patented products; Formularies, the lowest-priced products on lists...

• Budget buster.
  Tully, Shawn; Davis, Joyce E. // Joe Weider's Muscle & Fitness; Feb97, Vol. 58 Issue 2, p28 

  Reports on a study showing an increase in prices of prescription medicines in 1995. Aggressive price increases by the pharmaceutical industry since the failure of the national health care reform efforts.

• Greek drug price cuts will have knock on effects across Europe.
  Watson, Rory // BMJ: British Medical Journal (Overseas & Retired Doctors Edition; 6/12/2010, Vol. 340 Issue 7760, p1269 

  The article focuses on the implications of the decision of the Greek government to reduce the price of certain medicines by up to 27 percent for Greece and other European countries.

• Will Pharma Jump into the Patent Pool?
  Watson, Rory // Pharmaceutical Representative; Nov2010, Vol. 40 Issue 11, p8 

  The article reports on the development of the Medicines Patent Pool which is established by the UNITAID in July 2010 with the aim to reduce prices of existing drugs in the U.S.

• Controlling rising prescription drug costs.
  Watson, Rory // CMA Magazine; Apr96, Vol. 70 Issue 3, p35 

  Focuses on controlling rising prescription drug costs. Taking a closer look at prescription needs.

• Who will choose?
  Watson, Rory // Ardell Wellness Report; Winter91/92, Issue 27, p5 

  Focuses on to what extent should taxpayers underwrite wonder drugs. Two suggestions in making cost-benefit decisions.

• Pharma index.
  Lerner, Matthew // Chemical Market Reporter; 2/24/97, Vol. 251 Issue 8, p20 

  Presents the pharmaceutical index for week ending February 21, 1997 which reflects the prices of 8 representative materials in the sector and the quantity of each produced in 1993.

• Drugs and pharmaceuticals.
  Lerner, Matthew // Chemical Business; Jan1998, Vol. 12 Issue 1, p80 

  Reports on trends in drug prices in India, in 1997. Drug prices reduced by the National Pharmaceutical Pricing Authority; Factors influencing drug prices; Drugs with price revisions.

• Whose side are we on?
  Tosh, Mark // Medical Marketing & Media; Sep2003, Vol. 38 Issue 9, p6 

  Examines the debate over prescription drug prices in the United States. Pricing policies of the pharmaceutical industry; List legislative proposals that threaten the industry; 2003 career and salary survey of the periodical "Medical Marketing and Media".

Next 50 Results